Tropical Journal of Pharmaceutical Research
Journal / Tropical Journal of Pharmaceutical Research / Vol. 24 No. 1 (2025) / Articles

download PDF

Published:

Feb 11, 2025

Keywords:

Atherosclerotic cardiovascular disease, Blood lipids, YKL40, Phospholipase A2, Atorvastatin

Issue

Vol. 24 No. 1 (2025)

Section

Articles

Copyright (c) 2025 Author

Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.

All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.

Author Biographies

Cuijun Hao, Department of Heart Center, The Third Central Clinical College of Tianjin Medical University, China, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Department of Heart Center, The Third Central Hospital of Tianjin, China, Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, China, Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, China, Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin 300170, China and Vasculocardiology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.

Rui Wang, Vasculocardiology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.

Yang Hong, Vasculocardiology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.

Xiaoying Li, Vasculocardiology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.

Meng Ning, Department of Heart Center, The Third Central Clinical College of Tianjin Medical University, China, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Department of Heart Center, The Third Central Hospital of Tianjin, China, Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, China, Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, China and Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin 300170, China.

Cuijun Hao

Department of Heart Center, The Third Central Clinical College of Tianjin Medical University, China, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Department of Heart Center, The Third Central Hospital of Tianjin, China, Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, China, Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, China, Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin 300170, China and Vasculocardiology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.

Tianhua Hou

Department of Heart Center, The Third Central Clinical College of Tianjin Medical University, China, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Department of Heart Center, The Third Central Hospital of Tianjin, China, Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, China, Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, China and Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin 300170, China.

Fei Wang

Department of Heart Center, The Third Central Clinical College of Tianjin Medical University, China, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Department of Heart Center, The Third Central Hospital of Tianjin, China, Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, China, Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, China and Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin 300170, China.

Rui Wang

Vasculocardiology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.

Yang Hong

Vasculocardiology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.

Xiaoying Li

Vasculocardiology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.

Meng Ning

Department of Heart Center, The Third Central Clinical College of Tianjin Medical University, China, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Department of Heart Center, The Third Central Hospital of Tianjin, China, Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, China, Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, China and Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin 300170, China.

Yingwu Liu

Department of Heart Center, The Third Central Clinical College of Tianjin Medical University, China, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Department of Heart Center, The Third Central Hospital of Tianjin, China, Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, China, Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, China and Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin 300170, China.

Abstract

Purpose: To investigate the efficacy of atorvastatin in the treatment of atherosclerotic cardiovascular disease (ASCVD) Methods: A total of 158 patients who underwent coronary angiography in the Department of Cardiology, First Affiliated Hospital of Hebei North University, China were divided into acute myocardial infarction (AMI, n = 42), unstable angina pectoris (UAP, n = 70), and control (n = 46) groups. Atorvastatin (40 mg) was administered to the patients in AMI and UAP groups for 40 days. Triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, phospholipase A2 (PLA2), YKL40, and clinical efficacy were evaluated after treatment. Results: Acute myocardial infarction group (AMI) had significantly higher TC, LDL-C, non-HDL-C, PLA2, and YKL40 levels compared to UAP and control (p < 0.05). Also, HDL-C, TG, and TG/HDL-C were significantly higher in AMI and UAP compared to control group (p < 0.05). In coronary heart disease, TG/HDL-C had the highest sensitivity, and LDL-C had the highest specificity. Furthermore, TC, LDL-C, and TG significantly decreased in both AMI and UAP groups (p < 0.05), while HDL-C remained unchanged (p > 0.05). Conclusion: Atorvastatin effectively improves lipid profiles in ASCVD patients, and markers such as PLA2 and YKL40 effectively predict ASCVD risk. Further larger-scale, long-term studies are needed to validate the effectiveness of combining lipid and inflammatory biomarkers for ASCVD risk prediction and management.

Journal Identifiers

eISSN: 1596-9827
print ISSN: 1596-5996